Key result
Amiodarone reduces VF rearrest by an absolute ~59% during resuscitation with therapeutic hypothermia.
Why the study?
Amiodarone is administered during resuscitation, but its antiarrhythmic effects during targeted temperature management are unknown.
Does amiodarone worsen arrhythmia substrates or susceptibility to arrhythmias during resuscitation with targeted temperature management?
Does amiodarone worsen arrhythmia substrates or susceptibility to arrhythmias during resuscitation with targeted temperature management?
Amiodarone does not appear to be proarrhythmic when used during targeted temperature management post-cardiac arrest, suppressing recurrent VF despite altering repolarization parameters.
Answers are grounded in this paper and cite their sources.
Amiodarone may suppress recurrent VF without proarrhythmia during hypothermic resuscitation in animals; leaves open translation to clinical targeted temperature management.
Background Amiodarone is administered during resuscitation, but its antiarrhythmic effects during targeted temperature management are unknown. The purpose of this study was to determine the effect of both therapeutic hypothermia and amiodarone on arrhythmia substrates during resuscitation from cardiac arrest. Methods and Results We utilized 2 complementary models: (1) In vitro no‐flow global ischemia canine left ventricular transmural wedge preparation. Wedges at different temperatures (36°C or 32°C) were given 5 µmol/L amiodarone (36‐Amio or 32‐Amio, each n=8) and subsequently underwent ischemia and reperfusion. Results were compared with previous controls. Optical mapping was used to measure action potential duration, dispersion of repolarization (DOR), and conduction velocity (CV). (2) In vivo pig model of resuscitation. Pigs (control or targeted temperature management, 32–34°C) underwent ischemic cardiac arrest and were administered amiodarone (or not) after 8 minutes of ventricular fibrillation. In vitro: therapeutic hypothermia but not amiodarone prolonged action potential duration. During ischemia, DOR increased in the 32‐Amio group versus 32‐Alone (84±7 ms versus 40±7 ms, P <0.05) while CV slowed in the 32‐Amio group. Amiodarone did not affect CV, DOR, or action potential duration during ischemia at 36°C. Conduction block was only observed at 36°C (5/8 36‐Amio versus 6/7 36‐Alone, 0/8 32‐Amio, versus 0/7 32‐Alone). In vivo: QTc decreased upon reperfusion from ischemia that was ameliorated by targeted temperature management. Amiodarone did not worsen DOR or CV. Amiodarone suppressed rearrest caused by ventricular fibrillation (7/8 without amiodarone, 2/7 with amiodarone, P =0.041), but not pulseless electrical activity (2/8 without amiodarone, 5/7 with amiodarone, P =0.13). Conclusions Although amiodarone abolishes a beneficial effect of therapeutic hypothermia on ischemia‐induced DOR and CV, it did not worsen susceptibility to ventricular tachycardia/ventricular fibrillation during resuscitation.
No takes yet. Share an insight, caveat, or question.
Piktel et al. (2021) studied Ischemic cardiac arrest (n=21). Amiodarone and therapeutic hypothermia vs. Normal temperature without amiodarone, normal temperature with amiodarone, or therapeutic hypothermia alone was evaluated on Rearrest caused by ventricular fibrillation in vivo (p=0.041). During in vivo resuscitation, amiodarone suppressed rearrest caused by ventricular fibrillation without worsening susceptibility to arrhythmias during therapeutic hypothermia.
Synapse has enriched 10 related papers. Consider them for comparative context: